The Q2 print itself is a non-event for a pre-revenue biotech — the wider loss was expected given rising trial costs. The key catalysts are the darovasertib NDA filing (H2 2026) and data readouts at ESMO (October 2026). Monitor for FDA acceptance of the NDA and any updates on the IDE849 registrational trial design. The stock may trade on pipeline milestones rather than quarterly financials.
Price Chart
Executive Summary
IDEAYA Biosciences reported Q2 2026 results with a net loss of $112.5M ($-1.22/share), a wider loss than the prior quarter's $98.5M ($-1.11/share), driven by rising R&D spend ($108.7M vs $95.7M). The company highlighted ongoing NDA submission for darovasertib under RTOR, a new Roche collaboration for IDE892, and a strong cash position of ~$1.24B following a $323.4M June offering. The widening loss and lack of revenue growth (collaboration revenue of $8.9M is immaterial for a pre-commercial biotech) make this a neutral-to-slightly-bearish update, though the pipeline catalysts and cash runway into 2030 provide a floor.
Key Financial Metrics
Key Facts
- Net loss of $112.5M for Q2 2026, compared to $98.5M in Q1 2026.
- R&D expenses increased to $108.7M from $95.7M sequentially.
- Cash, cash equivalents, and marketable securities of ~$1.24B as of June 30, 2026.
- Completed a public offering in June 2026, raising ~$323.4M in net proceeds.
- NDA filing for darovasertib in metastatic uveal melanoma is underway under RTOR, completion expected H2 2026.
- Announced clinical collaboration with Roche to evaluate IDE892 in combination with RG6505 in pancreatic cancer.
- Cash runway guidance into 2030 remains unchanged.
Financial Impact
Net loss widened by $14M QoQ to $112.5M; cash position strengthened by ~$270M QoQ to $1.24B due to equity offering.
Risk Factors
- Darovasertib NDA may face regulatory delays or a Complete Response Letter.
- Clinical trial failures in the ADC or MTAP pipeline could reset valuation.
- Cash burn rate is accelerating; while runway extends to 2030, future dilution remains a risk if pipeline expands.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-331381 |
| Document: idya-20260804.htm | 0001193125-26-331381 |
| Document: 0001193125-26-331381-index-headers.html | 0001193125-26-331381 |
| Document: 0001193125-26-331381-index.html | 0001193125-26-331381 |
| Document: 0001193125-26-331381.txt | 0001193125-26-331381 |
| 8-K Data (Synthetic) | 0001193125-26-331381 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 8w ago | 8-K | $36.11 $39.95 | ▲ +10.63% | ▲ +11.87% | $37.05 (+2.60%) |
Jun 23, 2026 14w ago | 8-K | $36.28 $35.00 | ▼ −3.53% | ▼ −5.46% | $37.05 (+2.12%) |
Jun 10, 2026 16w ago | 8-K | $28.84 $37.28 | ▼ −29.26% | ▼ −27.37% | $37.05 (−28.47%) |
Jun 9, 2026 16w ago | 424B5 | $27.60 $37.28 | ▼ −35.07% | ▼ −31.45% | $37.05 (−34.24%) |
Jun 8, 2026 16w ago | 424B5 | $28.07 $40.51 | ▼ −44.32% | ▼ −42.87% | $37.05 (−31.99%) |
Jun 3, 2026 17w ago | 8-K | $28.40 $37.65 | ▲ +32.57% | ▲ +33.57% | $37.05 (+30.46%) |
May 5, 2026 21w ago | 8-K | $28.74 $28.40 | ▼ −1.18% | ▼ −3.96% | $37.05 (+28.91%) |
May 5, 2026 21w ago | 424B5 | $28.74 $28.40 | ▼ −1.18% | ▼ −3.96% | $37.05 (+28.91%) |
Apr 13, 2026 24w ago | 8-K | $32.82 $28.13 | ▼ −14.29% | ▼ −22.02% | $37.05 (+12.89%) |
Apr 9, 2026 25w ago | 8-K | $31.00 $28.74 | ▼ −7.29% | ▼ −14.86% | $37.05 (+19.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access